Professor Richard Hindley is the UK's lead surgeon for Rezūm steam treatment for BPH, offering this and other minimally invasive therapies, including Aquablation, across London and Hampshire
Professor Richard Hindley is an internationally recognised Consultant Urological Surgeon, Clinical Lead for Urology at Hampshire Hospitals NHS Foundation Trust and Visiting Professor of Knowledge Exchange at the University of Winchester. He specialises in minimally invasive treatment of benign prostatic hyperplasia (BPH), prostate cancer diagnostics and focal therapy, and treats patients at Urology Partners clinics in London and Hampshire.
BPH treatment: Rezūm, GreenLight Laser and Aquablation
Professor Hindley is the UK’s leading surgeon for Rezūm water vapour (steam) therapy for enlarged prostate. Demand for BPH consultations rose sharply after NICE recommendation of the treatment in August 2018, and his leadership in the field contributed significantly to that approval and to the procedure’s national adoption. He has now performed over 800 hundred Rezūm procedures and continues to collect outcome data so that results can be followed and compared in medical trials.
His BPH portfolio also includes:
- GreenLight Laser surgery: he pioneered one of the UK’s first day-case GreenLight programmes in 2005
- Aquablation water jet therapy
Prostate cancer diagnosis and focal therapy
Professor Hindley is one of Europe’s most experienced focal therapy practitioners, with over 15 years’ experience treating localised prostate cancer. His expertise includes:
- mpMRI and targeted fusion biopsy for accurate prostate cancer diagnosis
- Focal therapy (HIFU and cryotherapy) for localised prostate cancer
Under his leadership, Basingstoke has become a nationally recognised centre for prostate cancer diagnostics, imaging and focal therapy, receiving tertiary referrals from across the South of England.
Research and national leadership
- Key member of the PROMIS and PRECISION trial teams, which helped establish multiparametric MRI as the national standard for prostate cancer diagnosis
- Collaborates with UCL, Imperial College London and the University of Oxford
- Author of more than 100 prostate-related academic publications
- Specialist Adviser to NICE’s Interventional Procedures Programme
- Chair of the GIRFT Academy for Bladder Outlet Obstruction, addressing national variation in BPH care
Teaching and training
Professor Hindley has introduced advanced techniques, including laparoscopy, HIFU, GreenLight laser surgery and Rezūm, to centres across the UK. He holds an Honorary Senior Lectureship at the University of Southampton in recognition of his contribution to postgraduate training.
Qualifications and career
- Medical degree, University of Dundee (1991)
- MSc in Urology (1999), for research into bladder dysfunction
- Six years of specialist urology training in the South Thames region, including two years at King’s College Hospital
- Laparoscopic urology fellowship, University of Queensland, Brisbane (2003)
- Consultant Urological Surgeon, Basingstoke, since 2004
Where he practises
- London: HCA Princess Grace Hospital, King Edward VII and Welbeck
- Hampshire: The Hampshire Clinic and Candover Clinic
Outside work, he enjoys family life, cycling, tennis and photography.
Frequently asked questions
What does Professor Richard Hindley specialise in?
He specialises in BPH treatment (Rezūm, GreenLight Laser and Aquablation), prostate cancer diagnostics with mpMRI and fusion biopsy, and focal therapy with HIFU and cryotherapy.
Is Professor Hindley the UK’s lead surgeon for Rezūm?
Yes. He is the UK’s leading surgeon for Rezūm water vapour therapy and has performed several hundred procedures. His work contributed to NICE approval in August 2018.
What is Rezūm?
Rezūm is a minimally invasive treatment for BPH that uses water vapour (steam) to treat excess prostate tissue and relieve urinary symptoms.
Does Professor Hindley offer focal therapy for prostate cancer?
Yes. He has over 15 years’ experience of focal therapy, using HIFU and cryotherapy to treat localised prostate cancer.
